journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis Journal—Experimental, Translational and Clinical

journal
https://www.readbyqxmd.com/read/29707228/multiple-sclerosis-executive-dysfunction-task-switching-and-the-role-of-attention
#1
M Clough, P Foletta, A N Frohman, D Sears, A Ternes, O B White, J Fielding
Background: It has been suggested that switching ability might not be affected in multiple sclerosis (MS) as previously thought; however, whether this is true under more 'real-world' conditions when asymmetry in task difficulty is present has not been ascertained. Objective: The objective of this paper is to examine the impact of task difficulty asymmetry on task switching ability in MS. Method: An ocular motor (OM) paradigm that interleaves the simple task of looking towards a target (prosaccade, PS) with the cognitively more difficult task of looking away from a target (antisaccade, PS) was used...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29662683/coexistence-of-systemic-lupus-erythematosus-and-multiple-sclerosis-a-case-report-and-literature-review
#2
REVIEW
Elisa Carolina Jácome Sánchez, María Ariana García Castillo, Victor Paredes González, Fernando Guillén López, Edgar Patricio Correa Díaz
Multiple sclerosis (MS) and systemic lupus erythematous (SLE) are autoimmune diseases, the coexistence of which is uncommon in patients. Owing to the rarity of this condition, the distinction between MS and SLE is a diagnostic challenge for neurologists. We present a case report in which MS and SLE were present in the same patient. There are few case reports in the world on the association between MS and SLE. The following case report is the first of its kind in which both MS and SLE are present in a patient from a country with low prevalence of MS such as Ecuador...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29623216/feasibility-of-mesenchymal-stem-cell-culture-expansion-for-a-phase-i-clinical-trial-in-multiple-sclerosis
#3
Sarah M Planchon, Karen T Lingas, Jane Reese Koç, Brittney M Hooper, Basabi Maitra, Robert M Fox, Peter B Imrey, Kylie M Drake, Micheala A Aldred, Hillard M Lazarus, Jeffrey A Cohen
Background: Multiple sclerosis is an inflammatory, neurodegenerative disease of the central nervous system for which therapeutic mesenchymal stem cell transplantation is under study. Published experience of culture-expanding multiple sclerosis patients' mesenchymal stem cells for clinical trials is limited. Objective: To determine the feasibility of culture-expanding multiple sclerosis patients' mesenchymal stem cells for clinical use. Methods: In a phase I trial, autologous, bone marrow-derived mesenchymal stem cells were isolated from 25 trial participants with multiple sclerosis and eight matched controls, and culture-expanded to a target single dose of 1-2 × 106 cells/kg...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29568544/no-evidence-of-disease-activity-neda-analysis-by-epochs-in-patients-with-relapsing-multiple-sclerosis-treated-with-ocrelizumab-vs-interferon-beta-1a
#4
Eva Havrdová, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Shibeshih Belachew, Iain Bennett, Regine Buffels, Hideki Garren, Jian Han, Laura Julian, Julie Napieralski, Stephen L Hauser, Gavin Giovannoni
Background: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). Objective: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. Methods: NEDA was assessed in a modified intent-to-treat population ( n  = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg)...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29552356/prolonged-release-fampridine-as-adjunct-therapy-to-active-motor-training-in-ms-patients-a-pilot-double-blind-randomized-placebo-controlled-study
#5
François Jacques, Adrian Schembri, Avi Nativ, Chantal Paquette, Pawel Kalinowski
Background: Both prolonged-release fampridine (PRF) and enabling active motor training (EAMT) are beneficial in multiple sclerosis (MS) patients. Their combined effect is, however, understudied. Objective: The objective of this paper is to determine if PRF augments the beneficial effect of EAMT in MS patients as opposed to placebo. Method: This is a pilot, randomized, placebo-controlled, double-blind 14-week study. Participants were randomly assigned to receive PRF 10 mg BID ( n  = 21) or placebo ( n  = 20)...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29552355/severe-aquaporin-4-igg-positive-neuromyelitis-optica-with-disseminated-herpes-zoster-in-a-pregnant-woman-successfully-treated-with-intravenous-immunoglobulin
#6
Yuki Matsumoto, Mario Tsuchiya, Shakespear Norshalena, Chikako Kaneko, Jin Kubo, Teiji Yamamoto, Toshiyuki Takahashi, Kazuo Fujihara
A 26-year-old, 17-week pregnant woman developed aquaporin-4-IgG-positive severe longitudinally extensive transverse myelitis during the course of disseminated herpes zoster and became quadriparetic. She was unresponsive to high-dose intravenous methylprednisolone but became able to walk without assistance after intravenous immunoglobulin. One and a half months later, left optic neuritis developed but her vision improved with intravenous immunoglobulin. The only sequela was left T5 girdle sensation, and she delivered a healthy baby...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29497559/treadmill-walking-exercise-training-and-brain-function-in-multiple-sclerosis-preliminary-evidence-setting-the-stage-for-a-network-based-approach-to-rehabilitation
#7
Brian M Sandroff, Glenn R Wylie, Brad P Sutton, Curtis L Johnson, John DeLuca, Robert W Motl
Exercise training has been identified as a highly promising approach for managing the cognitive consequences of multiple sclerosis (MS). This study represents a secondary analysis of resting-state functional connectivity (RSFC) magnetic resonance imaging data from a pilot treadmill walking exercise training intervention for improving cognitive processing speed (CPS) in MS. There were large intervention effects on RSFC between the thalamus and right superior frontal gyrus ( d  = 1.92) and left medial frontal gyrus ( d  = 1...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29497558/risk-factors-for-fingolimod-induced-lymphopenia-in-multiple-sclerosis
#8
Ryohei Ohtani, Masahiro Mori, Tomohiko Uchida, Akiyuki Uzawa, Hiroki Masuda, Jia Liu, Satoshi Kuwabara
Background: Lymphopenia is a well-known adverse event of fingolimod, a disease-modifying drug for multiple sclerosis (MS). Objectives: The objective of this paper is to investigate risk factors for predicting fingolimod-induced lymphopenia in MS by frequent hematological monitoring. Methods: We retrospectively reviewed data of fingolimod-treated MS patients. Data assessed were sex, age, disease duration, medication history, body mass index, all attacks, Kurtzke's Expanded Disability Status Scale score, and absolute lymphocyte count (ALC) within two days before initiating fingolimod (baseline), on the day after first administration (day 2), and at least every other month after initiating fingolimod therapy...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29479457/a-randomized-study-to-evaluate-the-effect-of-exercise-on-fatigue-in-people-with-relapsing-remitting-multiple-sclerosis-treated-with-fingolimod
#9
M Mäurer, K Schuh, S Seibert, M Baier, C Hentschke, R Streber, A Tallner, K Pfeifer
Background: Fatigue is a major symptom of multiple sclerosis (MS) in patients, and it has been shown to improve with physical exercise. Although fingolimod might lessen fatigue, it is unclear how patients treated with fingolimod react to physical activity regarding fatigue. Objective: This study evaluated the effect of an exercise intervention on fatigue in relapsing-remitting MS patients receiving fingolimod. Methods: People with MS (PwMS) were randomized to either a structured internet-based exercise program (e-training) or no e-training intervention...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29383266/movement-measurements-at-home-for-multiple-sclerosis-walking-speed-measured-by-a-novel-ambient-measurement-system
#10
Victoria Mj Smith, Jonathan S Varsanik, Rachel A Walker, Andrew W Russo, Kevin R Patel, Wendy Gabel, Glenn A Phillips, Zebadiah M Kimmel, Eric C Klawiter
Background: Gait disturbance is a major contributor to clinical disability in multiple sclerosis (MS). A sensor was developed to assess walking speed at home for people with MS using infrared technology in real-time without the use of wearables. Objective: To develop continuous in-home outcome measures to assess gait in adults with MS. Methods: Movement measurements were collected continuously for 8 months from six people with MS. Average walking speed and peak walking speed were calculated from movement data, then analyzed for variability over time, by room (location), and over the course of the day...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29375889/national-estimates-of-self-reported-sitting-time-in-adults-with-multiple-sclerosis
#11
J E Sasaki, R W Motl, G Cutter, R A Marrie, T Tyry, A Salter
Background: Limited data exist on the prevalence and distribution of sedentary behavior (SB) in multiple sclerosis (MS). Objective: The objective of this paper is to describe sitting time as a metric of SB in a large national sample of people with MS. Methods: A total of 8004 individuals from the North American Research Committee on MS (NARCOMS) Registry completed the sitting time question from the International Physical Activity Questionnaire in spring 2015...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29372069/diagnosis-and-treatment-of-latent-tuberculosis-in-patients-with-multiple-sclerosis-expert-consensus-on-behalf-of-the-colombian-association-of-neurology-committee-of-multiple-sclerosis
#12
Carlos Navas, Carlos A Torres-Duque, Joe Munoz-Ceron, Carlos Álvarez, Juan R García, Luis Zarco, Lázaro A Vélez, Carlos Awad, Carlos Alberto Castro
Background: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic infections including tuberculosis. Objective: The purpose of this study was to obtain consensus from a panel of neurologists, pulmonologists, infectious disease specialists, and epidemiology experts regarding the diagnosis, treatment, and monitoring of latent tuberculosis in patients with multiple sclerosis...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29348927/improved-cognitive-performance-and-event-related-potential-changes-following-working-memory-training-in-patients-with-multiple-sclerosis
#13
Thomas J Covey, Janet L Shucard, Ralph Hb Benedict, Bianca Weinstock-Guttman, David W Shucard
Background: Few studies of cognitive rehabilitation in multiple sclerosis (MS) have targeted working memory specifically. Objective: We examined the effects of n -back working memory training on cognitive performance and brain function in patients with MS. Methods: Patients with MS ( n  = 12) and healthy controls (HC; n  = 12) underwent 20 sessions of n -back working memory training. Before and after training (pre- and posttest) cognitive event-related potential (ERP) measures were obtained during a 3-back task...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29348926/a-double-blind-placebo-controlled-single-ascending-dose-study-of-remyelinating-antibody-rhigm22-in-people-with-multiple-sclerosis
#14
Andrew Eisen, Benjamin M Greenberg, James D Bowen, Douglas L Arnold, Anthony O Caggiano
Objective: The objective of this paper is to assess, in individuals with clinically stable multiple sclerosis (MS), the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamics of the monoclonal recombinant human antibody IgM22 (rHIgM22). Methods: Seventy-two adults with stable MS were enrolled in a double-blind, randomized, placebo-controlled, single ascending-dose, Phase 1 trial examining rHIgM22 from 0.025 to 2.0 mg/kg. Assessments included MRI, MR spectroscopy, plasma PK, and changes in clinical status, laboratory values and adverse events for three months...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29339837/validation-of-the-brief-international-cognitive-assessment-for-multiple-sclerosis-in-japan
#15
Masaaki Niino, Toshiyuki Fukazawa, Jun-Ichi Kira, Tatsusada Okuno, Masahiro Mori, Nobuo Sanjo, Takashi Ohashi, Hikoaki Fukaura, Juichi Fujimori, Yuko Shimizu, Nobuhiro Mifune, Yusei Miyazaki, Eri Takahashi, Seiji Kikuchi, Dawn Langdon, Ralph Hb Benedict, Makoto Matsui
Background: The Brief International Cognitive Assessment for MS (BICAMS) is a practical battery for measuring cognitive function in multiple sclerosis (MS). Objectives: We aimed to validate a Japanese version of the BICAMS in patients with MS and healthy controls. Methods: The Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-Second Edition (CVLT2) and the Brief Visuospatial Memory Test Revised (BVMTR) were administered to 156 patients with MS and 126 healthy controls (HCs)...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29318030/environmental-temperature-and-exercise-modality-independently-impact-central-and-muscle-fatigue-among-people-with-multiple-sclerosis
#16
Geetika Grover, Michelle Ploughman, Devin T Philpott, Liam P Kelly, Augustine J Devasahayam, Katie Wadden, Kevin E Power, Duane C Button
Background: Heat sensitivity and fatigue limit the ability of multiple sclerosis patients to participate in exercise. Objective: The purpose of this study was to determine the optimal aerobic exercise parameters (environmental temperature and exercise modality) to limit exercise-induced central and muscle fatigue among people with multiple sclerosis. Methods: Fourteen people with multiple sclerosis with varying levels of disability completed four randomized exercise sessions at 65% of the maximal volume of oxygen: body-weight supported treadmill cool (16°C), body-weight supported treadmill room (21°C), total-body recumbent stepper cool and total-body recumbent stepper room...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29318029/thrombin-generation-correlates-with-disease-duration-in-multiple-sclerosis-ms-novel-insights-into-the-ms-associated-prothrombotic-state
#17
Martin Em Parsons, Karen O'Connell, Seamus Allen, Karl Egan, Paulina B Szklanna, Christopher McGuigan, Fionnuala Ní Áinle, Patricia B Maguire
Background: Thrombin is well recognised for its role in the coagulation cascade but it also plays a role in inflammation, with enhanced thrombin generation observed in several inflammatory disorders. Although patients with multiple sclerosis (MS) have a higher incidence of thrombotic disease, thrombin generation has not been studied to date. Objectives: The aim of this study was to characterise calibrated automated thrombography parameters in patients with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS) in comparison to healthy controls (HCs)...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29318028/interferon-beta-1b-in-treatment-na%C3%A3-ve-paediatric-patients-with-relapsing-remitting-multiple-sclerosis-two-year-results-from-the-betapaedic-study
#18
Jutta Gärtner, Wolfgang Brück, Almuth Weddige, Hannah Hummel, Christiane Norenberg, Jörg-Peter Bugge
Background and objective: Study evaluating Betaferon(R)'s safety and tolerability in paediatric patients with multiple sclerosis (BETAPAEDIC) is a prospective, open-label observational multicentre study to assess the safety and effectiveness of interferon beta-1b in paediatric patients with relapsing-remitting multiple sclerosis. Methods: Treatment-naïve patients (12-16 years) scheduled to start interferon beta-1b were enrolled with follow-up visits every six months for two years...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29276624/subcutaneous-interferon-%C3%AE-1a-three-times-weekly-and-the-natural-evolution-of-gadolinium-enhancing-lesions-into-chronic-black-holes-in-relapsing-and-progressive-multiple-sclerosis-analysis-of-prisms-and-spectrims-trials
#19
A Traboulsee, Dkb Li, R Tam, G Zhao, A Riddehough, J Fang, F Dangond, L Kappos
Background: Evolution of gadolinium-enhancing lesions into chronic black holes (CBH) may be reduced by interferon (IFN) therapy. Objective: The objective of this paper is to assess the effect of IFN β-1a and placebo on CBH evolution and disability in patients with relapsing-remitting multiple sclerosis (RRMS), as well as CBH evolution in patients with secondary progressive multiple sclerosis (SPMS). Methods: A post hoc, exploratory analysis of patients with RRMS and SPMS with monthly MRI scans (months -1 to 9) from two separate placebo-controlled clinical trials of IFN β-1a was conducted...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29270309/randomized-placebo-controlled-crossover-study-of-dalfampridine-extended-release-in-transverse-myelitis
#20
Kateryna Schwartz, Nicholas F Wymbs, Hwa Huang, Maureen A Mealy, Carlos A Pardo, Kathleen Zackowski, Michael Levy
Background: Dalfampridine has the potential to be effective in patients with transverse myelitis (TM) as this rare disorder shares some clinical and pathogenic similarities with multiple sclerosis. Methods: This is a randomized, double-blind, placebo-controlled crossover study of dalfampridine extended-release (D-ER, Ampyra®). Sixteen adult study participants with monophasic TM confirmed by MRI were enrolled if their baseline timed 25-foot walking speed was between 5 and 60 seconds...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
journal
journal
52506
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"